Highlights Launched Vision 2030Delivered Adjusted EBITDA margin of 19.1%Returned to positive packaging volume growth in second half of the yearAchieved Innovation Sales Growth of $205 millionExecuted ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 EPS, expectations were $1.85. Operator: Thank you for standing by. Welcome to ...

MIAMI, FL / ACCESS Newswire / February 4, 2025 / For decades, companies and policymakers have relied on carbon credits as a tool to combat environmental challenges. Yet, carbon credits have proven to ...

Both Opdivo and Keytruda are still in the foothills of ... However shareholders have raised questions about the compensation package of Vertex's CEO, Jeffrey Leiden, which topped $28 million ...

In particular, Keytruda for cancer represents a key blockbuster with multi-billion-dollar potential: It holds a first-mover advantage in one of the largest cancer indications of non-small cell ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...

As the Nasdaq weathers the Trump tariffs, Meta stock, Axon and CrowdStrike lead this barrage of breakout stocks.

MicroStrategy reports Q4 results late Wednesday. The software company went on a 12-week bitcoin buying spree ahead of results ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

Merck (MRK) stock sank like a stone on Tuesday after the pharmaceutical giant posted poor guidance for the rest of the year.